Product NDC: | 21695-996 |
Proprietary Name: | Lamivudine and Zidovudine |
Non Proprietary Name: | Lamivudine and Zidovudine |
Active Ingredient(s): | 150; 300 mg/1; mg/1 & nbsp; Lamivudine and Zidovudine |
Administration Route(s): | ORAL |
Dosage Form(s): | TABLET, FILM COATED |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 21695-996 |
Labeler Name: | Rebel Distributors Corp |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA079081 |
Marketing Category: | ANDA |
Start Marketing Date: | 20111227 |
Package NDC: | 21695-996-02 |
Package Description: | 2 TABLET, FILM COATED in 1 BOTTLE (21695-996-02) |
NDC Code | 21695-996-02 |
Proprietary Name | Lamivudine and Zidovudine |
Package Description | 2 TABLET, FILM COATED in 1 BOTTLE (21695-996-02) |
Product NDC | 21695-996 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | Lamivudine and Zidovudine |
Dosage Form Name | TABLET, FILM COATED |
Route Name | ORAL |
Start Marketing Date | 20111227 |
Marketing Category Name | ANDA |
Labeler Name | Rebel Distributors Corp |
Substance Name | LAMIVUDINE; ZIDOVUDINE |
Strength Number | 150; 300 |
Strength Unit | mg/1; mg/1 |
Pharmaceutical Classes | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |